C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption.

[1]  J. Vacca,et al.  L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. , 1998, Bioorganic & medicinal chemistry letters.

[2]  Michael Robert Wiley,et al.  Small-molecule direct thrombin inhibitors , 1997 .

[3]  J. Vacca,et al.  L-373,890, An achiral, noncovalent, subnanomolar thrombin inhibitor , 1997 .

[4]  J. Vacca,et al.  Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy. , 1997, Journal of medicinal chemistry.

[5]  D. Veber,et al.  Inhibition of Thrombin by Peptides Containing Lysyl-α-Keto Carbonyl Derivatives , 1995, Thrombosis and Haemostasis.

[6]  Kimball Sd.  Challenges in the development of orally bioavailable thrombin active site inhibitors. , 1995 .

[7]  G. Claeson.  Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[8]  P. Bernstein,et al.  Design of orally active, non-peptidic inhibitors of human leukocyte elastase. , 1994, Journal of Medicinal Chemistry.

[9]  Christopher M Thomas,et al.  Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogues. , 1992, Journal of medicinal chemistry.

[10]  G. Sandusky,et al.  Rat model of arterial thrombosis induced by ferric chloride. , 1990, Thrombosis research.

[11]  Robert W. Lang,et al.  Synthesis of selectively trifluoromethylated pyridine derivaties as potential antihypertensives , 1988 .

[12]  V. Martín,et al.  A greatly improved procedure for ruthenium tetroxide catalyzed oxidations of organic compounds , 1981 .